Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey

Basit Öğe Kaydı
dc.contributor.authorÖven Ustaalioğlu, Bala Başak
dc.contributor.authorBilici, Ahmet
dc.contributor.authorErkol Yılmaz, Burçak
dc.contributor.authorAliustaoğlu, Mehmet
dc.contributor.authorŞeker, Mesut
dc.contributor.authorVardar, Fügen
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:32Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:32Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect the decision on adjuvant chemotherapy, and also factors related to survival in stage IA breast cancer patients in Turkey. Methods: We retrospectively evaluated 347 stage IA patients. The relationship between the clinicopathological parameters and adjuvant chemotherapy was analyzed. Results: The median age and follow-up time were 52 years (range: 25-86) and 22.6 months (range: 1-113), respectively. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 87.9% and 98.7%, respectively, but the median DFS was not reached. Age, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and the presence of triple-negative breast tumor (TNBC) were related to DFS, and lymphovascular invasion (LVI), perineural invasion (PNI), HER2 status, the presence of TNBC, and recurrence were related to OS (p < 0.05). Furthermore, age, menopausal status, multicentricity, grade, tumor size, necrosis, ER, the presence of TNBC, and HER2 were found to be related to adjuvant therapy decision (p < 0.05). All these parameters, in addition to LVI and PNI, were independent factors for chemotherapy by logistic regression analysis. Conclusions: In decisions about adjuvant therapy in stage IA breast cancer patients, clinicopathological factors should be kept in mind.
dc.identifier.citationÖven Ustaalioğlu, B. B., Bilici, A., Erkol Yılmaz, B., Aliustaoğlu, M., Şeker, M., Vardar, F. ... Gümüş, M. (2014). Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey. Breast Care, 9(2), 123-127. https://dx.doi.org/10.1159/000360929
dc.identifier.doi10.1159/000360929
dc.identifier.endpage127
dc.identifier.issn1661-3791
dc.identifier.issue2
dc.identifier.scopusqualityQ3
dc.identifier.startpage123
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1192
dc.identifier.urihttps://dx.doi.org/10.1159/000360929
dc.identifier.volume9
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherS. Karger AG
dc.relation.ispartofBreast Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdjuvant Therapy
dc.subjectBreast Cancer
dc.subjectChemotherapy
dc.subjectStage IA
dc.titleImportant factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
bilici(2014).pdf
Boyut:
323.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu